Showing 1791-1800 of 2123 results for "".
- Fenfluramine Consistently Reduces Seizures in Children and Young Adults with Dravet Syndromehttps://practicalneurology.com/news/fenfluramine-consistently-reduces-seizures-in-children-and-young-adults-with-dravet-syndrome/2469374/A third phase 3 study (NCT02926898) further validates the significant reduction of convulsive seizures seen when individuals with Dravet syndrome (DS) receive fenfluramine (Fintepla; Zogenix Inc.,
- Cerebral Venous Thrombosis Incidence Is Increasinghttps://practicalneurology.com/news/cerebral-venous-thrombosis-incidence-is-increasing/2469362/A study published in Neurology, found that cerebral venous thrombosis (CVT) incidence is higher than previously reported and has also increased since 2006. Increased incidence was mainly in men and women more than age 45. Consistent with prior data, the incidence of CVT remained highest in younge
- New DNA-Plasmid Immunotherapy Treatment, in Combination with Cemiplimab, for Glioblastoma Results in 85% 1-Year Survival Ratehttps://practicalneurology.com/news/new-dna-plasmid-immunotherapy-treatment-in-combination-with-cemiplimab-for-glioblastoma-results-in-85-1-year-survival-rate/2469261/In a phase 1/2 clinical trial (NCT03491683), 85% (44 out of 52) of individuals newly diagnosed with glioblastoma multiforme (GBM) who received 2 new immunotherapeutic agents (INO-5401, INO-9012, I
- Children and Teens Caring for Their Parents with ALS Need More Education and Support From Other Youthhttps://practicalneurology.com/news/children-and-teens-caring-for-their-parents-with-als-need-more-education-and-support-from-other-youth/2469193/Children and teens with family members with amyotrophic lateral sclerosis (ALS) help with bathing, dressing, eating, and all types of caregiving activities. However, they may not have training or enough information about the disease. A study (published somewhere? if so state that; if not, s
- Children Treated Presymptomatically With Nusinersen Continue Surviving and Meeting Motor Milestones After 2 Years of Treatmenthttps://practicalneurology.com/news/children-treated-presymptomatically-with-nusinersen-continue-surviving-and-meeting-motor-milestones-after-2-years-of-treatment/2469037/As published in the journal Neuromuscular Disorders, 25 children who were genetically diagnosed with spinal muscular atrophy (SMA) and treated presymptomatically with nusinersen (Spinraza; Biogen, Cambridge,
- FDA Provides Expanded Clearance for Device to Treat Migraine in Childrenhttps://practicalneurology.com/news/fda-provides-expanded-clearance-for-device-to-treat-migraine-in-children/2468822/The Food and Drug Administration (FDA) has granted new marketing clearance for a device that provides acute and preventive treatment of migraine to include children 12 years of age and older. The technology (sTMS; eNeura, Inc., Baltimore, MD) is a non-invasive device that uses single-puls
- Plasma p-tau217 Clock Models Estimate Time to Symptomatic Alzheimer Diseasehttps://practicalneurology.com/news/plasma-p-tau217-clock-models-estimate-time-to-symptomatic-alzheimer-disease/2485769/A single plasma % phosphorylated tau217 (%p-tau217) measurement may estimate not only risk but also timing of symptomatic Alzheimer disease (AD) onset, according to a longitudinal cohort study published in Nature Medicine. In 2 independent cohorts, clock models based on plasma %p-tau217
- Maternal COVID-19 Exposure Linked to Neurodevelopmental Risk in Childrenhttps://practicalneurology.com/news/maternal-covid-19-exposure-linked-to-neurodevelopmental-risk-in-children/2485480/Children exposed to maternal COVID-19 (SARS-CoV-2 infection) in utero had a higher likelihood of receiving a neurodevelopmental diagnosis by age 3 years, with the strongest associations observed following third-trimester exposure and among male offspring, according to a large retrospective cohort
- Director of the National Institute of Neurological Disorders and Stroke Oustedhttps://practicalneurology.com/news/director-of-the-national-institute-of-neurological-disorders-and-stroke-ousted/2485145/The contract for Walter Koroshetz, MD, as Director of the National Institute of Neurological Disorders and Stroke (NINDS) has not been renewed, ending his leadership of the institute after 10 years. Dr. Koroshetz’s departure comes despite a positive internal review and a recommendation for reappo
- CTAD 2025 Honors Takeshi Iwatsubo, MD, PhD with Lifetime Achievement Awardhttps://practicalneurology.com/news/ctad-2025-honors-takeshi-iwatsubo-md-phd-with-lifetime-achievement-award/2484692/Takeshi Iwatsubo, MD, PhD was recognized at the 18th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference as the recipient of this year’s Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research. The award celebrates Dr. Iwatsubo’s decades of foundational work in Alzheime